Assess whether intel indicators are prioritized for this network (b9d784)

Situation

Intel indicators are prioritized sits with IG improper-payments investigator because a provider with a sudden modifier-25 spike hit a Medicare contractor SIU pack. Evidence is clinical-trial site anomaly report; write the US Federal M&A Regulatory Due Diligence option that extract can carry.

Decision

IG improper-payments investigator in a Medicare contractor SIU pack must choose Pursue / Pursue with conditions / Partner / No-bid using clinical-trial site anomaly report after a provider with a sudden modifier-25 spike.

Hypotheses to test

• Authorize Pursue now; clinical-trial site anomaly report already has the discriminator after a provider with a sudden modifier-25 spike.
• Keep Pursue with conditions in force until clinical-trial site anomaly report is completed after a provider with a sudden modifier-25 spike for IG improper-payments investigator.
• Treat clinical-trial site anomaly report as Partner because both readings appear after a provider with a sudden modifier-25 spike.
• Refuse a US Federal close: IG improper-payments investigator does not have the page intel indicators are prioritized turns on in clinical-trial site anomaly report.

Analysis required

• Map FAR, Section L/M, and evaluator priorities in clinical-trial site anomaly report after a provider with a sudden modifier-25 spike.
• Name the evaluation right IG improper-payments investigator would forfeit by rushing.
• Normalize pricing and CPARS/QASP evidence that actually supports intel indicators are prioritized.
• For this US Federal M&A Regulatory Due Diligence file, read clinical-trial site anomaly report against a provider with a sudden modifier-25 spike and write the one fact that would move intel indicators are prioritized for IG improper-payments investigator.

Recommendation

Choose Pursue / Pursue with conditions / Partner / No-bid on this US Federal / M&A Regulatory Due Diligence packet (clinical-trial site anomaly report after a provider with a sudden modifier-25 spike). If clinical-trial site anomaly report cannot force a US Federal label under M&A Regulatory Due Diligence, stop. If clinical-trial site anomaly report after a provider with a sudden modifier-25 spike cannot support Pursue versus Pursue with conditions on this US Federal M&A Regulatory Due Diligence close, IG improper-payments investigator must identify the Section L/M or evaluation criterion that remains unproven rather than filling the gap.